domingo, 20 de setembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond

View original at nasdaq.com
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond Key Points AbbVie provides an attractive combination of income, value, and growth…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Realty Income has particularly promising opportunities in Europe, where the total addressable market is $8.5 trillion and competition is limited

    60% confidence
  • Enbridge expects to deliver growth across all aspects of its business, especially in natural gas transmission

    60% confidence
  • The Federal Reserve is virtually paralyzed by uncertainty about inflation and the job market

    60% confidence
  • Enbridge has visible growth through the end of the decade, with roughly $50 billion of opportunities identified

    60% confidence
  • The 10 stocks identified by Stock Advisor could produce monster returns in the coming years

    60% confidence
  • Now is a great time to invest in dividend stocks with above-average yields

    60% confidence
  • AbbVie should deliver solid growth over the next few years driven by drugs like Rinvoq and Skyrizi and promising late-stage pipeline programs

    60% confidence

Data points we hold from this source

S&P 500 · healthcare sector forward pe ratio17.4 ratio
S&P 500 · forward pe ratio20 ratio
AbbVie Inc. · dividend increase streak53 years
AbbVie Inc. · forward pe ratio14.3 ratio
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
Sinalizamos conflitos abertamente ›
Verificado recentemente
Verificado com a fonte original
4,982
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,982 factos verificados com a fonte5,299 documentos-fonte arquivados
Consulte estes dados → isubstrate.com